The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s exhibiting significant potential in clinical trials for managing obesity. Unlike some available weight loss solutions, retatrutide appears to deliver a more substantial decreas